

# ASX Release

---

## SUDA LTD ANNOUNCES NEW MEDIA ARTICLE

**PERTH, AUSTRALIA – 9 November 2017:** SUDA LTD (ASX: SUD), a leader in oro-mucosal drug delivery, today announces that SUDA's novel OroMist® drug delivery technology was featured on Channel Nine's prime-time news. The story included extracts from an interview with Nick Woolf, SUDA's Chief Business Officer and real-life insights from a paediatrician and a parent with an epileptic child. A copy of the video can be accessed on the Company's website via the following link:

<http://www.sudaltd.com.au/index.php/media-news/98-channel-9-news-story>



**Further information:**

**STEPHEN CARTER**

**CHIEF EXECUTIVE OFFICER / MANAGING DIRECTOR**

**SUDA LTD**

Tel: +61 8 6142 5555

[sjcarter@sudaltd.com.au](mailto:sjcarter@sudaltd.com.au)

**NOTES TO EDITORS:**

**About SUDA LTD**

SUDA LTD (ASX: SUD) is a drug delivery company focused on oro-mucosal administration, headquartered in Perth, Western Australia. The Company is developing low-risk oral sprays using its OroMist® technology to reformulate existing pharmaceuticals. The many potential benefits of administering drugs through the oral mucosa (i.e.: cheeks, tongue, gums and palate) include ease of use, lower dosage, reduced side effects and faster response time. SUDA's product pipeline includes ZolpiMist™, a first-in-class oral spray of zolpidem for insomnia. ZolpiMist is marketed in the USA and SUDA has rights to the product outside of the US and Canada. SUDA's most advanced development-stage product, ArTiMist®, is a novel sublingual malaria treatment for children. In a Phase III trial, ArTiMist was shown to be superior to intravenous quinine. Other products in development include oral sprays for the treatment of migraine headache, chemotherapy-induced nausea and vomiting, erectile dysfunction and pre-procedural anxiety. For more information, visit [www.sudaltd.com.au](http://www.sudaltd.com.au)